Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novartis (GB:0QLR)
LSE:0QLR
0QLR Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF83.61 - CHF115.98
Previous CloseN/A
Volume210.36K
Average Volume (3M)1.16M
Market Cap
CHF191.46B
Enterprise ValueCHF193.96B
Total Cash (Recent Filing)7.78B
Total Debt (Recent Filing)17.90B
Price to Earnings (P/E)18.4
Beta0.60
Next Earnings
Apr 29, 2025EPS Estimate
1.83Next Dividend Ex-Date
Mar 11, 2025Dividend Yield3.44%
Share Statistics
EPS (TTM)5.21
Shares Outstanding2,189,930,400
10 Day Avg. Volume264,004
30 Day Avg. Volume1,158,229
Standard Deviation0.05
R-Squared0.08
Alpha-0.00185
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF99.92Price Target Upside11.22% Upside
Rating ConsensusHold
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
AcquisitionNovartis announced the acquisition of Anthos Therapeutics Inc., a privately held clinical-stage biotech company with lead asset abelacimab, in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Financial PerformanceGroup core operating profit came in 9% above consensus expectations with a better adjusted operating profit margin due to a better product mix and cost-containment initiatives.
Market PotentialThe anticoagulation market is worth around $20bn, suggesting a potential $5bn market for abelacimab in patients ineligible for oral anticoagulation.
Bears Say
Generic CompetitionThere is a potential risk of an earlier than expected generic launch for Entresto, which could negatively impact EPS.
Growth ChallengesPost-2028, Novartis faces growth challenges due to the loss of exclusivity on key drugs like Cosentyx, Kesimpta, and Kisqali.
Trial ResultsAbelacimab failed to show a benefit on stroke in the Phase II AZALEA-TIMI-71 trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
8.87% Mutual Funds
0.01% Other Institutional Investors
81.85% Public Companies and
Individual Investors
0QLR FAQ
What was Novartis’s price range in the past 12 months?
Novartis lowest share price was CHF83.61 and its highest was CHF115.97 in the past 12 months.
What is Novartis’s market cap?
Novartis’s market cap is CHF191.46B.
When is Novartis’s upcoming earnings report date?
Novartis’s upcoming earnings report date is Apr 29, 2025 which is in 65 days.
How were Novartis’s earnings last quarter?
Novartis released its earnings results on Jan 31, 2025. The company reported CHF1.781 earnings per share for the quarter, beating the consensus estimate of CHF1.623 by CHF0.157.
Is Novartis overvalued?
According to Wall Street analysts Novartis’s price is currently Undervalued.
Does Novartis pay dividends?
Novartis pays a Annually dividend of CHF3.299 which represents an annual dividend yield of 3.44%. See more information on Novartis dividends here
What is Novartis’s EPS estimate?
Novartis’s EPS estimate is 1.83.
How many shares outstanding does Novartis have?
Novartis has 2,189,930,400 shares outstanding.
What happened to Novartis’s price movement after its last earnings report?
Novartis reported an EPS of CHF1.781 in its last earnings report, beating expectations of CHF1.623. Following the earnings report the stock price went up 3.129%.
Which hedge fund is a major shareholder of Novartis?
Currently, no hedge funds are holding shares in GB:0QLR
---
0QLR Stock 12 Month Forecast
Average Price Target
CHF99.92
▲(11.22% Upside)
Technical Analysis
Best Analysts Covering 0QLR
1 Year
1 Year Success Rate
19/22 ratings generated profit
1 Year Average Return
+10.63%
reiterated a buy rating 26 days ago
Copying David Evans's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +10.63% per trade.
---